The purpose of this work package, led by Epidemico, is to provide access to classified social media data via a visualisation platform for signal identification and confirmation. Formal analysis of emerging social media data could better predict problems with marketed medicines products and inform better design of future medicines products. Data from social media could provide earlier estimates of the magnitude and nature of a safety signal. However, these data have not previously been used for safety surveillance. Careful consideration must therefore be given to how to process the information to make it suitable while meeting , keeping to data protection requirements. The WP2a team will expand the platform to include two non-English European languages.

Users of social media can easily opt-out of data collection.

Partners involved

  • Epidemico
  • Novartis Pharma
  • Janssen Pharmaceutica
  • AstraZeneca
  • UCB